Protect Benefit-Risk
  • Home
  • Recommendations
  • Methods
  • Visualisations
  • Case Studies
  • Patient and Public Involvement
  • About Us
  • Links and Glossary
  • Efalizumab
  • Natalizumab
  • Rimonabant
  • Rosiglitazone
  • Telithromycin
  • Warfarin
  • Introduction
  • Which methodologies were tested?
  • What are the lessons learned?
  • What are the key messages?
  • Resources

What are the key messages?

Please see "Lessons learned".


  • Disclaimer
  • Copyright Policy
  • Contact Us
  • Protect Benefit-Risk
  • Protect Benefit-Risk